Test Price
2,800 AED✅ Home Collection Available
INHBA Gene FSH Releasing Protein Deficiency Genetic Test in UAE
Executive Summary & Core Metrics
Advanced genetic test to identify pathogenic and likely pathogenic variants in the INHBA gene associated with FSH releasing protein (activin) deficiency, leading to congenital hypogonadotropic hypogonadism and reproductive disorders. The laboratory delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited next-generation sequencing with comprehensive variant interpretation.
Test Overview & Methodology
This NGS-based genetic test analyses the entire coding region and splice sites of the INHBA gene to detect single nucleotide variants, small insertions and deletions, and copy number variations that disrupt activin biosynthesis. Activin is the principal hypothalamic-pituitary-gonadal axis modulator; its deficiency leads to impaired FSH secretion, delayed puberty, and infertility. The assay provides whole-gene coverage exceeding 500x, ensuring detection of mosaic variants and low-level somatic mutations.
Bioinformatics analysis employs a validated AI-powered variant calling pipeline aligned to GRCh38/hg38, with population frequency filtering against gnomAD and ClinVar. All reportable variants are manually reviewed by a consultant medical geneticist and classified according to ACMG/AMP 2015 guidelines. The final report includes pharmacogenomic annotations where relevant.
| Feature | Our NGS Test | Targeted Sanger Sequencing |
|---|---|---|
| Precision (Analytical Sensitivity) | 99.9% (whole-gene coverage >500x) | ~95% (selected exons only) |
| Method | NGS with AI-powered variant calling (Illumina NovaSeq X Plus) | Conventional capillary electrophoresis |
| Speed (TAT) | 3–4 weeks (comprehensive report) | 6–8 weeks (stepwise testing) |
| Variant Types Detected | SNVs, indels, copy number variations (CNV) | SNVs and small indels only |
Physician Insight & Safety Protocols
A Clinician’s Note from Mrs. Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA: 9294403)
“This molecular assay provides definitive identification of INHBA-related hypogonadotropic hypogonadism, yet it is essential to correlate genetic results with detailed clinical phenotyping, including Tanner staging, serum gonadotropin levels, and anosmia assessment. No single laboratory test replaces a comprehensive neuroendocrine evaluation. Patients presenting with acute headache, visual field deficits, or significant hormonal instability should undergo immediate emergency assessment.”
Advisory: Pre-Test Counseling & Contraindications
- Mandatory Counseling: Pre-test genetic counseling with a DHA-registered genetic counselor is required before sample collection to obtain informed consent and construct a three-generation pedigree.
- Exclusion Criteria: Recent blood transfusion within 30 days, active hematologic malignancy, or any acute unstable medical condition precluding venipuncture.
- Emergency Red Flags: Sudden severe headache with nausea, visual field loss, acute testicular pain, or signs of adrenal crisis – proceed to the nearest emergency department immediately.
⚠️ Never discontinue prescribed hormone therapy without consulting your treating endocrinologist.
Critical Exclusion Reminder
This test is not appropriate for individuals with acquired hypogonadotropic hypogonadism secondary to structural pituitary lesions, infiltrative disorders, or medication-related suppression. A dedicated MRI pituitary protocol and comprehensive endocrine workup remain the first-line investigations in such cases. Genetic testing should follow only after these etiologies have been ruled out.
Patient FAQ & Clinical Guidance
1. What is the INHBA gene test, and when is it recommended?
This NGS test identifies INHBA variants causing FSH releasing protein deficiency, aiding diagnosis of congenital hypogonadotropic hypogonadism. It is indicated for individuals with normosmic hypogonadotropic hypogonadism, unexplained low FSH/LH levels, delayed puberty, or infertility where a genetic etiology is suspected. A detailed family history of reproductive disorders strengthens the indication.
2. How is the sample collected, and does the 2800 AED fee include home service?
A certified phlebotomist collects a peripheral whole blood sample (5 mL in EDTA) via standard venipuncture; the 2800 AED fee covers all home collection logistics and genetic counseling. The sample is transported in an ISO-certified cold-chain container to the central laboratory. Results are delivered securely within 3–4 weeks. Insurance billing is coordinated directly via WhatsApp at +971 54 548 8731.
3. Is genetic counselling mandatory before this test?
Yes, pre-test genetic counselling is mandatory under DHA regulatory standards. Our DHA-registered genetic counsellor will help draw a detailed pedigree chart, explain potential outcomes, and obtain written informed consent. No fasting is required; bring all previous hormone reports, imaging studies, and any prior genetic test results.
4. How long does it take to receive results, and how are they delivered?
The turnaround time is 3–4 weeks from sample receipt at the laboratory. Results are delivered via a secure digital portal and a printed copy is sent to your registered address. A board-certified clinical geneticist provides a telephonic consultation to explain the findings and guide appropriate specialist referrals.
5. Can this test detect carriers for family planning?
Yes, the test accurately identifies heterozygous carriers of recessive INHBA variants. Carrier detection allows for informed reproductive planning, including preimplantation genetic testing and prenatal diagnosis. A genetic counsellor will discuss recurrence risks and available options during the post-test consultation.
UAE Regulatory & Data Privacy Adherence
Patient Data Protection & Clinical Safety Compliance
All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety, patient consent, and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License Number 1143.
Your genetic information is encrypted, access-controlled, and never shared with third parties without explicit written consent. You have the right to access, correct, and request deletion of your data in accordance with PDPL provisions.
Clinical & Logistical Metadata
| Test Name | INHBA Gene FSH Releasing Protein Deficiency Genetic Test (NGS Whole Gene Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (21–28 calendar days) |
| Sample Type / Matrix | Peripheral whole blood (EDTA Lavender Top Tube, 5 mL) |
| Methodology Used | Next-Generation Sequencing (NGS) with AI-powered variant calling; Illumina NovaSeq X Plus platform; whole-gene coverage >500x |
| ICD-10-CM Code | E23.0 (Hypopituitarism – gonadotropin deficiency) |
| LOINC Code | 92822-6 (Genetic analysis of a specific gene by next generation sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians